Sun Pharma Advanced Research Company rights issue history
NSE: SPARCBSE: 532872Pharmaceuticals & BiotechnologySmall Cap
Sun Pharma Advanced Research Company Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 2007
Last close ₹182.66up ₹3.42 (1.91%)BSE ₹182.55
Share price at the NSE close on 28 Oct 2026. Previous close ₹179.24.
28 Oct: open ₹180.63, high ₹184.30, low ₹178.35
52-week range of traded prices to 28 Oct 2026
₹108.00Low, 23 Mar 2026₹289.00High, 8 Jul 2026
- Next results date: the board meets on 2 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹5,928 Cr778th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 3.74
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.43
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record.
- 118.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 84.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.42
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 4,34,66631.5% delivered
Sun Pharma Advanced Research Company has made no bonus issue or split since Jul 2007; its other changes to its shares on record are below.
Rights issues
Every one on record, latest first.
- Rights issue · 16 Mar 2016 · record date 17 Mar 20165 new shares offered for every 116 held at ₹245 a share, face value plus a premium of ₹244. Open 28 Mar 2016 to 13 Apr 2016.
- Rights issue · 23 Aug 2012 · record date 25 Aug 20121 new share offered for every 7 held at ₹67 a share, face value plus a premium of ₹66.